# A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

> **NCT01729754** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 1090 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab 200 mg
- **DRUG:** Tildrakizumab 100 mg
- **DRUG:** Tildrakizumab Placebo
- **DRUG:** Etanercept Placebo
- **DRUG:** Etanercept 50 mg

## Key facts

- **NCT ID:** NCT01729754
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-05
- **Primary completion:** 2015-09-28
- **Final completion:** 2021-10-26
- **Target enrollment:** 1090 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01729754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01729754, "A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01729754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*